Company / Return on Equity (ROE)
UroGen Pharma Ltd. Return on Equity (ROE) History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-1317.3%
FY2022
5-year range
-1317.3% / -1317.3%
FY2018-FY2022
Trend
+0.0%
vs FY2021
Sector context
#190 of 190
Health Care
What the data says
UroGen Pharma Ltd. reports negative total equity of -1317.3% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-1317.3% in FY2022 with a 5-year CAGR of -1288.1%.
Declined from -58.3% to -1317.3% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -1295.0pp
- 5-Year Change
- -1288.1pp
- 10-Year Change
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 190This company -1317.3% Sector average -50.3%
▼
-2517.9% below sector average
Key checks
Key Insights
- In FY2022, return on equity (roe) increased 0.0% year-over-year.
- Currently 1266.9pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -1317.3% | +0.0% |
| FY2021 | -1317.3% | -2158.7% |
| FY2020 | -58.3% | -162.7% |
| FY2019 | -22.2% | +73.6% |
| FY2018 | -84.0% | -187.7% |
| FY2017 | -29.2% | -145.3% |
| FY2016 | -11.9% | - |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026